Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDanielle S. WallaceRRRobert ReddIVIoulia Vogiatzi

Discussion

Loading...

Member takes

Overview

Phase II trial reveals rituximab and epcoritamab achieves 97% overall response rate in high-tumor burden follicular lymphoma, suggesting improved outcomes.

Key Points

  • To evaluate the efficacy and safety of rituximab and epcoritamab as first-line treatment for high-tumor burden follicular lymphoma.
  • Phase II trial with previously untreated patients with grade 1-3A follicular lymphoma
  • Patients received debulking therapy with rituximab followed by epcoritamab
  • Response evaluated using PET-CT based on Lugano 2014 criteria after specified cycles
  • 97% overall response rate observed with 91% achieving complete metabolic response
  • Median follow-up of 8.6 months showed a 9-month progression-free survival of 97%
  • Cytokine release syndrome occurred in 43% of patients, lower in those receiving more epcoritamab doses

Cite This Study

Wallace et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4bdhttps://doi.org/10.1182/blood-2025-464
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma2025
  3. 3Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations
  4. 4Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025 · 14 citations
  5. 5Epcoritamab with rituximab + lenalidomide (R<sup>2</sup>) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.2024 · 9 citations